Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension
FJ Frey, A Odermatt, BM Frey - Current opinion in nephrology and …, 2004 - journals.lww.com
FJ Frey, A Odermatt, BM Frey
Current opinion in nephrology and hypertension, 2004•journals.lww.comRecently, mineralocorticoid receptor antagonists have been used in the randomized
aldactone evaluation study (RALES) with spironolactone, the eplerenone post-AMI heart
failure efficacy and survival study (EPHESUS), and in severe and postmyocardial infarct
heart failure, respectively. These investigations cannot be understood on the basis of the
present physiological knowledge and underscore the relevance of focusing on
mineralocorticoid receptor activation by ligands other than aldosterone.
aldactone evaluation study (RALES) with spironolactone, the eplerenone post-AMI heart
failure efficacy and survival study (EPHESUS), and in severe and postmyocardial infarct
heart failure, respectively. These investigations cannot be understood on the basis of the
present physiological knowledge and underscore the relevance of focusing on
mineralocorticoid receptor activation by ligands other than aldosterone.
Summary
Recently, mineralocorticoid receptor antagonists have been used in the randomized aldactone evaluation study (RALES) with spironolactone, the eplerenone post-AMI heart failure efficacy and survival study (EPHESUS), and in severe and postmyocardial infarct heart failure, respectively. These investigations cannot be understood on the basis of the present physiological knowledge and underscore the relevance of focusing on mineralocorticoid receptor activation by ligands other than aldosterone.
Lippincott Williams & Wilkins